Status:
RECRUITING
Tessa Jowell BRAIN MATRIX - Platform Study
Lead Sponsor:
University of Birmingham
Collaborating Sponsors:
The Brain Tumour Charity
University of Oxford
Conditions:
Glioma
Eligibility:
All Genders
16+ years
Brief Summary
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and acc...
Detailed Description
Gliomas, a type of brain tumour, are the most common primary tumour of the central nervous system (CNS) and in 2016 there were 5250 deaths from brain tumours in the UK. However, brain tumours are a ch...
Eligibility Criteria
Inclusion
- Newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample.
- Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis).
- Valid written informed consent for the study.
Exclusion
- Primary spinal cord tumours
- Active treatment of other malignancy
- Contraindication to MRI
- Patients without standard of care imaging available
Key Trial Info
Start Date :
November 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04274283
Start Date
November 24 2020
End Date
March 1 2027
Last Update
December 13 2024
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom, B15 2TH
2
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom, CB2 0QQ
3
NHS Lothian
Edinburgh, United Kingdom, EH4 2XU
4
Queen Elizabeth Unviersity Hospital, NHS Greater Glasgow and Clyde Health Board
Glasgow, United Kingdom, G51 4TF